- Replicas Corporation RGEN entered into a strategic partnership and exclusive License Agreement with DRS Daylight Solutions to expand the use of Mid-Infrared (Mid-IR) technology in the bioprocessing market.
- Through this agreement, Repligen assumes responsibility for the commercialization of Culpeo and the development of future products and technologies in partnership with DRS Daylight Solutions.
- Also read: Catalent-Repligen merger “seems unlikely,” says this analyst.
- Both companies will focus on expanding the portfolio of Quantum Cascade Laser Mid-IR (QCL-IR) based solutions and integrating these solutions with Repligen chromatography and filtration systems to expand their presence in the Process Analytics Technology (PAT) segment .
- Daylight’s patented QCL-IR technology measures higher-order protein and nucleic acid structures, facilitating the measurement of protein aggregation, concentration, nucleic acid content, and other critical attributes in biological manufacturing processes.
- DRS Daylight Solutions entered the bioprocessing market in 2018 with its groundbreaking Culpeo instrument.
- Price promotion: RGEN shares are down 5.43% to $212.97 on Tuesday’s latest check.
© 2022 Benzinga.de. Benzinga does not provide investment advice. All rights reserved.
[ad_2]
Source story
